Core Viewpoint - Zhejiang Haisen Pharmaceutical Co., Ltd. plans to reduce its shareholding by a maximum of 124,300 shares, accounting for 0.0816% of the total share capital, due to personal funding needs [1] Group 1 - The share reduction will occur between December 26, 2025, and March 25, 2026, through centralized bidding transactions [1] - The reduction plan was announced on December 4, 2025, and is currently in the implementation phase [1]

Group 1 - The core point of the article is that Haisen Pharmaceutical has approximately 10,000 shareholders as of February 10, 2026 [2]

Group 1 - The core point of the article is that Haisen Pharmaceutical has approximately 10,000 shareholders as of January 31, 2026 [2]

Group 1 - The company announced the appointment of Lixin Certified Public Accountants (Special General Partnership) as the auditing firm for the fiscal year 2025 [1] - Originally, Mr. Zhao Zhidong and Mr. Hong Jianliang were designated as the signing auditors, but due to a work adjustment for Mr. Zhao, the signing auditors have been changed to Mr. Hong Jianliang and Mr. Li Qingju [1] - The updated signing auditors for the company's 2025 audit project are Mr. Hong Jianliang and Mr. Li Qingju [1]

证券代码：001367 证券简称：海森药业 公告编号：2026-002 浙江海森药业股份有限公司 关于变更签字注册会计师的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江海森药业股份有限公司（以下简称"公司"）于 2025 年 3 月 26 日、2025 年 4 月 25 日分别召开第三届董事会第十二次会议和 2024 年年度股东大会，审议 通过了《关于公司续聘立信会计师事务所（特殊普通合伙）为 2025 年审计机构 的议案》，同意续聘立信会计师事务所（特殊普通合伙）（以下简称"立信"） 为公司 2025 年度审计机构。具体内容详见公司于 2025 年 3 月 28 日披露在巨潮 资讯网(www.cninfo.com.cn)上的《关于拟续聘会计师事务所的公告》（公告编号： 2025-012）。 2026 年 1 月 27 日，公司收到立信送达的《关于签字注册会计师变更的告知 函》，现将具体情况公告如下： （二）独立性和诚信记录情况 一、变更情况 立信为公司 2025 年度审计机构，原指派洪建良先生、赵智栋先生作为签字 注册会计师，为公司提供审计服务。 ...

Group 1 - The core point of the article is that Haisen Pharmaceutical (001367) has approximately 10,400 shareholders as of January 10, 2026 [1]

证券代码：001367 证券简称：海森药业 公告编号：2026-001 二、董事及部分高级管理人员减持计划实施完成的情况 浙江海森药业股份有限公司 关于公司部分董事、高级管理人员减持计划实施完成 及部分高级管理人员提前终止减持计划的公告 本公司董事、高级管理人员代亚先生、张胜权先生、楼岩军先生、潘爱娟 女士、胡康康先生保证向本公司提供的信息内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 浙江海森药业股份有限公司（以下简称"公司"）于 2025 年 12 月 5 日披露 了《关于公司董事、高级管理人员减持股份的预披露公告》（公告编号：2025-061）， 公司董事代亚先生、副总经理张胜权先生、副总经理楼岩军先生、财务总监潘爱 娟女士、董事会秘书胡康康先生计划自上述公告披露之日起 15 个交易日后的 3 个月内（即 2025 年 12 月 26 日至 2026 年 3 月 25 日）以集中竞价交易方式合计 减持公司股份不超过 124,320 股，即不超过公司总股本的 0.0816%。 一、部分高级管理人员提前终止减持计划的情况 公 ...

（七）培训对象：公司董事、高级管理人员、部分中层以上管理人员及公司 控股股东和实际控制人等相关人员 （八）培训内容：根据《深圳证券交易所股票上市规则（2025 年修订）》《深 圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作（2025 年修订）》《上市公司募集资金监管规则》等规则要求，本次培训重点向培训对象 介绍了最新监管政策、2025 年深圳证券交易所主板上市公司规范运作新规要求、 募集资金监管新规要求，通过法规与监管处罚案例相结合的方式，加深了公司董 事、高级管理人员、部分中层以上管理人员及公司控股股东和实际控制人等相关 人员对相关法律法规、上市公司规范运作及信息披露要求的理解，有助于提高公 司的规范运作和信息披露水平。 中信证券股份有限公司 关于浙江海森药业股份有限公司 2025年度持续督导培训情况的报告 深圳证券交易所： 中信证券股份有限公司（以下简称"中信证券"、"保荐人"）根据《深圳证券 交易所上市公司自律监管指引第 13 号——保荐业务（2025 年修订）》对浙江海 森药业股份有限公司（以下简称"海森药业"、"公司"）进行了 2025 年度持续督 导培训，报告如下： 一、本次持 ...

Summary of Key Points Core Viewpoint - The company announced that several executives, including the director Dai Ya and vice general managers Zhang Shengquan and Lou Yanjun, along with the secretary Hu Kangkang, have collectively reduced their holdings by 102,900 shares, representing 0.0675% of the total share capital between December 26 and December 31, 2025 [1] Group 1: Share Reduction Details - Dai Ya reduced his holdings by 24,420 shares [1] - Zhang Shengquan and Lou Yanjun each reduced their holdings by 25,530 shares [1] - Hu Kangkang also reduced his holdings by 24,420 shares [1] - Financial director Pan Aijuan reduced her holdings by 3,000 shares at an average price of 22.06 yuan per share [1] - Pan Aijuan has terminated the remaining plan to reduce 21,420 shares [1]

Group 1 - Company has been recognized as a national-level "specialized, refined, distinctive, and innovative" small giant enterprise by the Ministry of Industry and Information Technology, which enhances its brand recognition and industry influence [1][2] - The company specializes in chemical pharmaceutical raw materials and intermediates, which are crucial components of the pharmaceutical manufacturing industry, positioned upstream in the supply chain [1] - The company has cultivated a range of high-market-share products, including Sulfate Aluminum, Paracetamol, Atorvastatin Calcium, and PHBA, while expanding sales and market share for products like Escitalopram Oxalate and Parecoxib Sodium in recent years [1] Group 2 - The company has over 20 years of experience in the pharmaceutical industry, focusing on innovation, quality control, and reliable commercial reputation, which strengthens its core competitiveness and market influence [2] - The company has received multiple honors, including recognition as a "specialized and innovative" small enterprise in Zhejiang Province and various awards for quality and contribution to the local economy [2] - The company emphasizes technological innovation and has established a technical innovation system, collaborating with research institutions and universities to enhance R&D capabilities and market value realization [3] Group 3 - The company is committed to continuous R&D, production, and promotion of excellent pharmaceutical products and services, aiming to improve the quality of life [3] - The company plans to focus on the R&D, production, and sales of chemical pharmaceutical raw materials, intermediates, and formulations, pursuing a specialized development path [3] - The establishment of a pilot workshop will create an industrial R&D platform, facilitating the scaling up of new products and enhancing production capacity [3]